LogicBio Therapeutics, a preclinical gene editing biotech developing therapies for rare diseases, raised $70 million by offering 7 million shares at $10, below the range of $12 to $14. It had previously filed to offer 5.8 million shares at the same range. LogicBio Therapeutics plans to list on the Nasdaq under the symbol LOGC. Jefferies, Barclays and William Blair acted as lead managers on the deal.
